devimistat devimistat devimistat (inn; development code cpi-613) is an experimental anti-mitochondrial drug being developed by cornerstone pharmaceuticals. it is being studied for the treatment of patients with metastatic pancreatic cancer and relapsed or refractory acute myeloid leukemia (aml). devimistatclinical dataother namescpi-613legal statuslegal status investigational identifiers iupac name 6,8-bis(benzylsulfanyl)octanoic acid cas number95809-78-2pubchem cid24770514drugbank12109chemspider28189062uniie76113ir49chemblchembl3186849comptox dashboard (epa)dtxsid70914807 echa infocard100.231.125 chemical and physical dataformulac22h28o2s2molar mass388.58 g·mol−13d model (jsmol)interactive image smiles c1=cc=c(c=c1)csccc(ccccc(=o)o)scc2=cc=cc=c2 inchi inchi=1s/c22h28o2s2/c23-22(24)14-8-7-13-21(26-18-20-11-5-2-6-12-20)15-16-25-17-19-9-3-1-4-10-19/h1-6,9-12,21h,7-8,13-18h2,(h,23,24)key:zyrlhjimtrotbo-uhfffaoysa-n devimistat's mechanism of action differs from other drugs, operating on the tricarboxylic acid cycle and inhibiting enzymes involved with cancer cell energy metabolism. a lipoic acid derivative different from standard cytotoxic chemotherapy, devimistat is currently being studied in combination with modified folfirinox to treat various solid tumors and heme malignancies. regulation the u.s. food and drug administration (fda) has designated devimistat as an orphan drug for the treatment of pancreatic cancer, aml, myelodysplastic syndromes (mds), peripheral t-cell lymphoma, and burkitt's lymphoma, and given approval to initiate clinical trials in pancreatic cancer and aml. clinical trials clinical trials of the drug are underway including a phase iii open-label clinical trial to evaluate efficacy and safety of devimistat plus modified folfirinox (mffx) versus folfirinox (ffx) in patients with metastatic adenocarcinoma of the pancreas.